LUCIA MARIA MATTEI DE ARRUDA CAMPOS
Projetos de Pesquisa
Unidades Organizacionais
Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/36 - Laboratório de Pediatria Clínica, Hospital das Clínicas, Faculdade de Medicina
LIM/36 - Laboratório de Pediatria Clínica, Hospital das Clínicas, Faculdade de Medicina
35 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 35
- Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: an international collaboration(2014) MOORTHY, Lakshmi Nandini; ROY, Elizabeth; KURRA, Vamsi; PETERSON, Margaret G. E.; HASSETT, Afton L.; LEHMAN, Thomas J. A.; SCOT, Christiaan; EL-GHONEIMY, Dalia; SAAD, Shereen; FEKY, Reem El; AL-MAYOUF, Sulaiman; DOLEZALOVA, Pavla; MALCOVA, Hana; HERLIN, Troels; NIELSEN, Susan; WULFFRAAT, Nico; ROYEN, Annet van; MARKS, Stephen D.; BELOT, Alexandre; BRUNNER, Jurgen; HUEMER, Christian; FOELDVARI, Ivan; HORNEFF, Gerd; SAURENMAN, Traudel; SCHROEDER, Silke; PRATSIDOU-GERTSI, Polyxeni; TRACHANA, Maria; UZIEL, Yosef; AGGARWAL, Amita; CONSTANTIN, Tamas; CIMAZ, Rolando; GIANI, Theresa; CANTARINI, Luca; FALCINI, Fernanda; MANZONI, Silvia Magni; RAVELLI, Angelo; RIGANTE, Donato; ZULIAN, Fracnceso; MIYAMAE, Takako; YOKOTA, Shumpei; SATO, Juliana; MAGALHAES, Claudia S.; LEN, Claudio A.; APPENZELLER, Simone; KNUPP, Sheila Oliveira; RODRIGUES, Marta Cristine; SZTAJNBOK, Flavio; ALMEIDA, Rozana Gasparello de; JESUS, Adriana Almeida de; CAMPOS, Lucia Maria de Arruda; SILVA, Clovis; LAZAR, Calin; SUSIC, Gordana; AVCIN, Tadej; CUTTICA, Ruben; BURGOS-VARGAS, Ruben; FAUGIER, Enrique; ANTON, Jordi; MODESTO, Consuelo; VAZQUEZ, Liza; BARILLAS, Lilliana; BARINSTEIN, Laura; STERBA, Gary; MALDONADO, Irama; OZEN, Seza; KASAPCOPUR, Ozgur; DEMIRKAYA, Erkan; BENSELER, SusaBackground: Rheumatic diseases in children are associated with significant morbidity and poor health-related quality of life (HRQOL). There is no health-related quality of life (HRQOL) scale available specifically for children with less common rheumatic diseases. These diseases share several features with systemic lupus erythematosus (SLE) such as their chronic episodic nature, multi-systemic involvement, and the need for immunosuppressive medications. HRQOL scale developed for pediatric SLE will likely be applicable to children with systemic inflammatory diseases. Findings: We adapted Simple Measure of Impact of Lupus Erythematosus in Youngsters (SMILEY (c)) to Simple Measure of Impact of Illness in Youngsters (SMILY (c)-Illness) and had it reviewed by pediatric rheumatologists for its appropriateness and cultural suitability. We tested SMILY (c)-Illness in patients with inflammatory rheumatic diseases and then translated it into 28 languages. Nineteen children (79% female, n= 15) and 17 parents participated. The mean age was 12 +/- 4 years, with median disease duration of 21 months (1-172 months). We translated SMILY (c)-Illness into the following 28 languages: Danish, Dutch, French (France), English (UK), German (Germany), German (Austria), German (Switzerland), Hebrew, Italian, Portuguese (Brazil), Slovene, Spanish (USA and Puerto Rico), Spanish (Spain), Spanish (Argentina), Spanish (Mexico), Spanish (Venezuela), Turkish, Afrikaans, Arabic (Saudi Arabia), Arabic (Egypt), Czech, Greek, Hindi, Hungarian, Japanese, Romanian, Serbian and Xhosa. Conclusion: SMILY (c)-Illness is a brief, easy to administer and score HRQOL scale for children with systemic rheumatic diseases. It is suitable for use across different age groups and literacy levels. SMILY (c)-Illness with its available translations may be used as useful adjuncts to clinical practice and research.
- Safety and immunogenicity of influenza A(H3N2) component vaccine in juvenile systemic lupus erythematosus(2023) AIKAWA, Nadia Emi; BORBA, Eduardo Ferreira; BALBI, Verena Andrade; SALLUM, Adriana Maluf Elias; BUSCATTI, Izabel Mantovani; CAMPOS, Lucia Maria Arruda; KOZU, Katia Tomie; GARCIA, Cristiana Couto; CAPAO, Artur Silva Vidal; PROENCA, Adriana Coracini Tonacio de; LEON, Elaine Pires; DUARTE, Alberto Jose da Silva; LOPES, Marta Heloisa; SILVA, Clovis Artur; BONFA, EloisaIntroduction Seasonal influenza A (H3N2) virus is an important cause of morbidity and mortality in the last 50 years in population that is greater than the impact of H1N1. Data assessing immunogenicity and safety of this virus component in juvenile systemic lupus erythematosus (JSLE) is lacking in the literature.Objective To evaluate short-term immunogenicity and safety of influenza A/Singapore (H3N2) vaccine in JSLE.Methods 24 consecutive JSLE patients and 29 healthy controls (HC) were vaccinated with influenza A/Singapore/INFIMH-16-0019/2016(H3N2)-like virus. Influenza A (H3N2) seroprotection (SP), seroconversion (SC), geometric mean titers (GMT), factor increase in GMT (FI-GMT) titers were assessed before and 4 weeks post-vaccination. Disease activity, therapies and adverse events (AE) were also evaluated.Results JSLE patients and controls were comparable in current age [14.5 (10.1-18.3) vs. 14 (9-18.4) years, p = 0.448] and female sex [21 (87.5%) vs. 19 (65.5%), p = 0.108]. Before vaccination, JSLE and HC had comparable SP rates [22 (91.7%) vs. 25 (86.2%), p = 0.678] and GMT titers [102.3 (95% CI 75.0-139.4) vs. 109.6 (95% CI 68.2-176.2), p = 0.231]. At D30, JSLE and HC had similar immune response, since no differences were observed in SP [24 (100%) vs. 28 (96.6%), p = 1.000)], SC [4 (16.7%) vs. 9 (31.0%), p = 0.338), GMT [162.3 (132.9-198.3) vs. 208.1 (150.5-287.8), p = 0.143] and factor increase in GMT [1.6 (1.2-2.1) vs. 1.9 (1.4-2.5), p = 0.574]. SLEDAI-2K scores [2 (0-17) vs. 2 (0-17), p = 0.765] and therapies remained stable throughout the study. Further analysis of possible factors influencing vaccine immune response among JSLE patients demonstrated similar GMT between patients with SLEDAI < 4 compared to SLEDAI >= 4 (p = 0.713), as well as between patients with and without current use of prednisone (p = 0.420), azathioprine (p = 1.0), mycophenolate mofetil (p = 0.185), and methotrexate (p = 0.095). No serious AE were reported in both groups and most of them were asymptomatic (58.3% vs. 44.8%, p = 0.958). Local and systemic AE were alike in both groups (p > 0.05).Conclusion This is the first study that identified adequate immune protection against H3N2-influenza strain with additional vaccine-induced increment of immune response and an adequate safety profile in JSLE. (www.clinicaltrials.gov, NCT03540823).
conferenceObject Retinal vasculitis (RV) in pediatric population: case series(2020) GIAMPIETRO, Barbara; SOUTO, Fernanda Maria Silveira; TAKIUTI, Julia Tieme; CAMPOS, Lucia Maria Arruda; HIRATA, Carlos Eduardo; YAMAMOTO, Joyce H.- Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trial(2022) VANNI, Tazio; THOME, Beatriz C.; SPARROW, Erin; FRIEDE, Martin; FOX, Christopher B.; BECKMANN, Anna Marie; HUYNH, Chuong; MONDINI, Gabriella; SILVEIRA, Daniela H.; VISCONDI, Juliana Y. K.; BRAGA, Patricia Emilia; SILVA, Anderson da; SALOMAO, Maria da Graca; PIORELLI, Roberta O.; SANTOS, Joane P.; GATTAS, Vera Lucia; LUCCHESI, Maria Beatriz B.; OLIVEIRA, Mayra M. M. de; KOIKE, Marcelo E.; KALLAS, Esper G.; CAMPOS, Lucia M. A.; COELHO, Eduardo B.; SIQUEIRA, Marilda A. M.; GARCIA, Cristiana C.; MIRANDA, Milene Dias; PAIVA, Terezinha M.; TIMENETSKY, Maria do Carmo S. T.; ADAMI, Eduardo A.; AKAMATSU, Milena A.; HO, Paulo Lee; PRECIOSO, Alexander R.The emergence of potentially pandemic viruses has resulted in preparedness efforts to develop candidate vaccines and adjuvant formulations. We evaluated the dose-sparing effect and safety of two distinct squalene-based oil-in-water adjuvant emulsion formulations (IB160 and SE) with influenza A/H7N9 antigen. This phase I, randomized, double-blind, placebo-controlled, dose-finding trial (NCT03330899), enrolled 432 healthy volunteers aged 18 to 59. Participants were randomly allocated to 8 groups: 1A) IB160 + 15 mu g H7N9, 1B) IB160 + 7.5 mu g H7N9, 1C) IB160 + 3.75 mu g H7N9, 2A) SE + 15 mu g H7N9, 2B) SE + 7.5 mu g H7N9, 2C) SE + 3.75 mu g H7N9, 3) unadjuvanted vaccine 15 mu g H7N9 and 4) placebo. Immunogenicity was evaluated through haemagglutination inhibition (HI) and microneutralization (MN) tests. Safety was evaluated by monitoring local and systemic, solicited and unsolicited adverse events (AE) and reactions (AR) 7 and 28 days after each study injection, respectively, whereas serious adverse events (SAE) were monitored up to 194 days post-second dose. A greater increase in antibody geometric mean titers (GMT) was observed in groups receiving adjuvanted vaccines. Vaccinees receiving IB160-adjuvanted formulations showed the greatest response in group 1B, which induced an HI GMT increase of 4.7 times, HI titers >= 40 in 45.2% of participants (MN titers >= 40 in 80.8%). Vaccinees receiving SE-adjuvanted vaccines showed the greatest response in group 2A, with an HI GMT increase of 2.5 times, HI titers >= 40 in 22.9% of participants (MN titers >= 40 in 65.7%). Frequencies of AE and AR were similar among groups. Pain at the administration site and headache were the most frequent local and systemic solicited ARs. The vaccine candidates were safe and the adjuvanted formulations have a potential dose-sparing effect on immunogenicity against influenza A/H7N9. The magnitude of this effect could be further explored.
- Extensive cervical lymphadenitis mimicking bacterial adenitis as the first presentation of Kawasaki disease(2015) ROSSI, Felipe de Souza; SILVA, Marco Felipe Castro da; KOZU, Kátia Tomie; CAMARGO, Luís Fernando Aranha; ROSSI, Flávia Feijó Panico; SILVA, Clovis Artur; CAMPOS, Lúcia Maria de ArrudaCervical adenitis >1.5cm in diameter is the less frequently observed criteria in patients with Kawasaki disease and it is usually found in association with other symptoms during the acute phase. Moreover, the finding of fever and lymphadenitis with intense local signs of inflammation and phlegmon is rarely seen as the initial manifestation of Kawasaki disease. We report the case of a 7-year-old boy who had cervical lymphadenitis with adjacent cellulitis and phlegmon mimicking bacterial adenitis as the first presentation of Kawasaki disease. The patient had fever, cervical lymphadenitis with adjacent cellulitis, and severe headache. Cefadroxil was prescribed based on the clinical diagnosis of bacterial adenitis. Because he remained febrile and phlogistic signs worsened, after 1 day of hospitalization, antibiotics were administrated intravenously (ceftriaxone and oxacillin). The computed tomography of the neck showed primary infectious/inflammatory process. On the fourth day, the patient had dry and scaly lips, and treatment with oxacillin was replaced by clindamycin because the patient was still febrile. On the ninth day, he presented non-exudative bilateral conjunctival injection. On the tenth day of febrile disease, a rash appeared on his trunk, hands and feet. Patient’s symptoms resolved after intravenous administration of immunoglobulin (2g/kg/dose), and he was discharged 2 days later. On the 14th day, the patient had lamellar desquamation of fingers. Kawasaki disease should be considered as a differential diagnosis in children with febrile cervical lymphadenitis unresponsive to empiric antibiotics even if they have adjacent cellulitis and phlegmon.
- Guidelines for the management and treatment of periodic fever syndromes Cryopyrin-associated periodic syndromes (cryopyrinopathies - CAPS)(2016) TERRERI, Maria Teresa R. A.; BERNARDO, Wanderley Marques; LEN, Claudio Arnaldo; SILVA, Clovis Artur Almeida da; MAGALHAES, Cristina Medeiros Ribeiro de; SACCHETTI, Silvana B.; FERRIANI, Virginia Paes Leme; PIOTTO, Daniela Gerent Petry; CAVALCANTI, Andre de Souza; MORAES, Ana Julia Pantoja de; SZTAJNBOKI, Flavio Roberto; OLIVEIRA, Sheila Knupp Feitosa de; CAMPOS, Lucia Maria Arruda; BANDEIRA, Marcia; SANTOS, Flavia Patricia Sena Teixeira; MAGALHAES, Claudia SaadObjective: To establish guidelines based on cientific evidences for the management of cryopyrin associated periodic syndromes. Description of the evidence collection method: The Guideline was prepared from 4 clinical questions that were structured through Pico (Patient, Intervention or indicator, Comparison and Outcome), to search in key primary scientific information databases. After defining the potential studies to support the recommendations, these were graduated considering their strength of evidence and grade of recommendation. Results: 1215 articles were retrieved and evaluated by title and abstract; from these, 42 articles were selected to support the recommendations. Recommendations: 1. The diagnosis of Caps is based on clinical history and clinical manifestations, and later confirmed by genetic study. Caps may manifest itself in three phenotypes: FCAS (mild form), MWS (intermediate form) and Cinca (severe form). Neurological, ophthalmic, otorhinolaryngological and radiological assessments may be highly valuable in distinguishing between syndromes; 2. The genetic diagnosis with NLRP3 gene analysis must be conducted in suspected cases of Caps, i.e., individuals presenting before 20 years of age, recurrent episodes of inflammation expressed by a mild fever and urticaria; 3. Laboratory abnormalities include leukocytosis and elevated serum levels of inflammatory proteins; 4. Targeted therapies directed against interleukin-1 lead to rapid remission of symptoms in most patients. However, there are important limitations on the long-term safety. None of the three anti-IL-1 beta inhibitors prevents progression of bone lesions.
- Body Composition and Phase Angle: How to Improve Nutritional Evaluation in Juvenile Dermatomyositis Patients(2023) PUGLIESE, Camila; DELGADO, Artur Figueiredo; KOZU, Katia Tomie; CAMPOS, Lucia Maria de Arruda; AIKAWA, Nadia Emi; SILVA, Clovis Artur; ELIAS, Adriana Maluf(1) Background: This study aimed to assess body composition (BC) using bioelectrical impedance and food intake in juvenile dermatomyositis (JDM) patients. Associations between BC and physical activity, disease activity/cumulative damage and health-related quality of life parameters were also evaluated; (2) Methods: This was a cross-sectional study with 30 consecutive JDM patients (18 female and 12 male) and 24 healthy volunteers (14 female and 10 male) of both sexes followed at our pediatric rheumatology unit. The gathering of anthropometric and dietary data, and the performance of physical activity and bioelectrical impedance were undertaken in face-to-face meetings and through questionnaires. Clinical and therapeutic data were collected from medical records according to information from routine medical appointments; (3) Results: The frequency of high/very high body fat was significantly higher in controls compared with JDM patients (66.7% vs. 91.7%; p = 0.046). The median phase angle was significantly lower in patients compared with controls (5.2 & PLUSMN; 1.3 vs. 6.1 & PLUSMN; 1.0; p = 0.016). Body fat and lean mass were positively correlated with disease duration (r(s) = +0.629, p < 0.001 and r(s) = +0.716, p < 0.001, respectively) and phase angle (PhA) (r(s) = +0.400, p = 0.029 and r(s) = +0.619, p < 0.001, respectively). JDM patients with PhA & GE; 5.5 presented higher lean mass when compared with patients with PhA < 5.5 (p = 0.001); (4) Conclusions: Bioelectrical impedance can be a useful auxiliary exam in the medical and nutritional follow-up of JDM patients, because it seems to impact functional ability. These findings may assist professionals when advising JDM patients about the importance of physical activity and healthy eating in the preservation of lean mass.
- Fatal cryptococcal meningitis in a juvenile lupus erythematosus patient(2014) CAVALCANTE, Erica G.; MONTONI, Joao D.; OLIVEIRA, Guilherme T.; CAMPOS, Lucia M. A.; PAZ, Jose A.; SILVA, Clovis A.Cryptococcosis is a fungal infection caused by Cryptococcus neoformans, generally associated with immunodeficiency and immunosuppressive agents, and it is rarely reported in systemic lupus erythematosus (SLE), particularly in juvenile SLE (JSLE). From January 1983 to June 2011, 5,604 patients were followed at our University Hospital and 283 (5%) of them met the American College of Rheumatology (ACR) classification criteria for SLE. Only one (0.35%) of our JSLE patients had cryptococcal meningitis and is described in this report. A 10-year old girl was diagnosed with JSLE. By the age of 15 years, she presented persistent headaches, nausea and vomiting for a 5 day period without fever, after a cave-exploring trip. At that moment, she was under 10 mg/day of prednisone, azathioprine and hydroxychloroquine. A lumbar puncture was performed and India ink preparation was positive for cryptococcosis, cerebrospinal fluid culture yielded Cryptococcus neoformans and serum cryptococcal antigen titer was 1:128. Azathioprine was suspended, and liposomal amphotericin B was introduced. Despite of treatment, after four days she developed amaurosis and fell into a coma. A computer tomography of the brain showed diffuse ischemic areas and nodules suggesting fungal infection. Four days later, she developed severe sepsis and vancomycin and meropenem were prescribed, nevertheless she died due to septic shock. In conclusion, cryptococcal meningitis is a rare and severe opportunistic infection in juvenile lupus population. This study reinforces the importance of an early diagnosis and prompt introduction of antifungal agents, especially in patients with history of contact with bird droppings.
- Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases(2022) AIKAWA, Nadia Emi; BALBI, Verena Andrade; BORBA, Eduardo Ferreira; TONACIO, Adriana Coracini; SALLUM, Adriana Maluf Elias; CAMPOS, Lucia Maria Arruda; KOZU, Katia Tomie; VENDRAMINI, Margarete Borges; FONTOURA, Nicole; AZEVEDO, Adriana de Souza; SCHWARCZ, Waleska Dias; SARTORI, Ana Marli Christovam; ANTONANGELO, Leila; SILVA, Clovis Artur; BONFA, EloisaYellow fever vaccine (YFV) is a live attenuated vaccine usually contraindicated for juvenile autoimmune rheumatic disease (JARD) patients. During the recent epidemic in Sao Paulo-Brazil, YFV was indicated for patients under low immunosuppression. Thirty JARD patients with inactive diseases undergoing low immunosuppression and 30 healthy controls (HC) were vaccinated with a fractional dose 17DD YFV (similar to 5495 IU) and evaluated 30 days later. JARD patients and controls had comparable median age (12.4 vs. 12 years, p = 0.250). Disease parameters remained stable 30 days after 17DD YFV (p > 0.05) and only mild adverse events were reported in both groups (p > 0.05). JARD and HC had similar seroprotection [93% vs. 100%;p = 0.49], seroconversion rates [96% vs. 100%;p = 0.489], and GMT [1249 vs.1293; p = 0.821]. Both groups had similar white-blood-cells kinetics with transient decreases in lymphocytes at D5 and neutrophils at D10, followed by full recovery at D30 (P < 0.05). In conclusion, 17DD YFV was safe and immunogenic in JARD. This study may contribute to recommendations for patients living/travelling to endemic areas. (C) 2021 The Authors.
- Pyomyositis in childhood-systemic lupus erythematosus(2016) BLAY, Gabriela; FERRIANI, Mariana P. L.; BUSCATTI, Izabel M.; FRANCA, Camila M. P.; CAMPOS, Lucia M. A.; SILVA, Clovis A.Pyomyositis is a pyogenic infection of skeletal muscle that arises from hematogenous spread and usually presents with localized abscess. This muscle infection has been rarely reported in adult-onset systemic lupus erythematous (SLE) and, to our knowledge, has not been diagnosed in pediatric lupus population. Among our childhood-onset SLE (C-SLE) population, including 289 patients, one presented pyomyositis. This patient was diagnosed with C-SLE at the age of 10 years-old. After six years, while being treated with prednisone, azathioprine and hydroxychloroquine, she was hospitalized due to a 30-day history of insidious pain in the left thigh and no apparent trauma or fever were reported. Her physical examination showed muscle tenderness and woody induration. Laboratory tests revealed anemia, increased acute phase reactants and normal muscle enzymes. Computer tomography of the left thigh showed collection on the middle third of the vastus intermedius, suggesting purulent stage of pyomyositis. Treatment with broad-spectrum antibiotic was initiated, leading to a complete clinical resolution. In conclusion, we described the first case of pyomyositis during childhood in pediatric lupus population. This report reinforces that the presence of localized muscle pain in immunocompromised patients, even without elevation of muscle enzymes, should raise the suspicion of pyomyositis. A prompt antibiotic therapy is strongly recommended.